Astrazeneca Vaccine Set To Get UK Regulator Clearance By Year-End: Report

0
The Oxford University vaccine against COVID-19 being produced by AstraZeneca is likely to get regulatory approval from the UK's independent regulator by the end of this year for a rollout to begin in early 2021, according to a UK media report. The Medicines and Healthcare Regulatory Agency (MHRA), which had been formally tasked by the UK government last month with...

India Plans Early Vaccine Launch As Oxford University Deliveries Run Late

0
India raced ahead with work on its coronavirus vaccine while Britain's AstraZeneca said its deliveries were running "a little bit late" as countries around the world sought to conquer the pandemic and rescue their economies. A vaccine is seen as the world's best bet for taming a virus that has infected more than 48 million people, led to more than...

Covaxin Triggers Immune Response, No Adverse Effects In Phase 1 Trial

0
Covaxin - one of three coronavirus vaccine candidates being considered for emergency use authorisation in India - induced an immune response and registered no serious adverse events, interim findings of Phase I trials have revealed. The vaccine induced a neutralising antibody (an immune response) and was well-tolerated in all dose groups with no vaccine-related serious adverse events, pre-publication data showed. After the...

Centre approved anti-viral medicines to treat COVID-19 patients, says SC

0
The Supreme Court on Wednesday said there was an approval by the Central government on use of Remdesivir and Fabiparivir as medicines to treat COVID-19. The top court was hearing a plea seeking registration of an FIR by the CBI against ten Indian pharmaceutical firms for manufacturing and selling these two medicines for treating COVID-19 patients allegedly without...

China Coronavirus Vaccine May Be Ready For Public In November: Official

0
Coronavirus vaccines being developed in China may be ready for use by the general public as early as November, an official with the China Centre for Disease Control and Prevention (CDC) said. China has four COVID-19 vaccines in the final stage of clinical trials. At least three of those have already been offered to essential workers under an emergency...

Funds managed by MOPE invest in Pathkind Diagnostics

0
MOPE
Mumbai, 20th May 2022: India Business Excellence Fund – IV, a fund managed and advised by MOPE (MO Alternate Investment Advisors Private Limited ), has agreed to make a primary investment of upto INR 194.4 crore (USD 25 million) in Pathkind Diagnostics Private Limited (“Pathkind”/ “Company”), a pathology focused diagnostics services chain with operations across 23 states in India. Established in 2016, Pathkind is one of the fastest growing diagnostics services chain in India. It is promoted by Mr. Sanjeev Vashishta and the promoters of Mankind Pharma. Pathkind operates...

“Don’t Agree With Rs 80,000 Crore Figure For COVID Vaccine Distribution”: Centre

0
The Union Health Ministry has said it does not agree with the ₹ 80,000 crore figure cited by Adar Poonawalla, CEO of Serum Institute of India - the world's largest manufacturer of vaccines by volume and which is conducting trials of Covid vaccine candidates ahead of mass production - for buying and distributing the vaccine in the country. The...

Nua partners with Deepika Padukone to transform menstrual wellness in India

0
Nua
Bengaluru, April 30th, 2022: Onto becoming every Indian woman’s menstrual health companion, leading Femtech brand Nua has announced TIME100 honouree, actor Deepika Padukone as the face of the brand for its Menstrual wellness products such as Sanitary Pads, Cramp Comfort, Intimate Wash and Panty Liners. Being one of the top Femtech brands, Nua aims to help every Indian woman priorities their...

Govt removes price cap on innovative drugs for first 5 years

0
New Delhi: The government on Thursday exempted innovative medicines developed by foreign companies from price control for five years, giving Indian patients access to drugs that are currently only available abroad. These include orphan drugs that are used for treating rare medical conditions. Govt removes price cap on innovative drugs for first 5 years In amendments to the Drugs...

PharmEasy gets $300 mn funding; to use it for Thyrocare deal

0
PharmEasy, which acquired diagnostic chain Thyrocare, has raised $300 million from its existing investors. The funding will be used for the ongoing acquisition process of Thyrocare. Once the deal is complete the online pharmacy will aim to list the company on the Indian bourses.